Our News
CN Bio makes key senior appointments to support international commercial development
Appointments include James Craven as Chief Commercial Officer and Brian Manning as US Head of Sales Cambridge, UK, 05 August 2020: CN Bio, a leading cell culture company that has developed single and multi-organ microphysiological systems (MPS) to improve the accuracy...
CN Bio and Cambridge University identify novel regulatory pathway driving NASH
Paper published in Nature Metabolism demonstrates novel pathway regulating the underlying mechanism of liver fibrosis Research harnesses CN Bio’s liver-on-chip NASH disease model, to advance development of potential new medicines for liver fibrosis CN Bio, a...
CN Bio Innovations raises $9 million USD (c. £6.9 million GBP)
Investment will support commercial development in key markets, US and Europe Funding led by CITIC Securities Investment and supported by existing investor CN Innovations Headquarters relocated to larger premises in Cambridge Science Park, a leading UK life sciences...
NASH Drug Discovery Service Launched at AASLD
Leading bioengineering company CN Bio has launched a fee for service program providing Human Organ-on-Chip data to scientists studying non-alcoholic steatohepatitis (NASH) therapeutics. CN Bio launched the program at the American Association for the Study of Liver...
Sydney’s AXT offers Organ-on-Chip systems in Asia Pacific region
Organ-on-Chip specialist CN Bio has signed a distribution agreement with Sydney-based AXT Pty. Ltd., Australia’s leading supplier of high technology scientific equipment. The agreement will see AXT distribute CN Bio’s innovative bioengineering products to medical...
CN Bio to bring 10 organs together on a chip
London Organ-on-Chip specialist CN Bio today announced it has secured an exclusive license to technology from the Massachusetts Institute of Technology for Organ-on-Chip systems which connect human tissues from up to 10 organs. CN Bio participated with MIT on a...
PhysioMimix™ Human 3D Cell Culture wins Lab Innovation 2018 Award
The PhysioMimix™ benchtop 3D cell culture system from CN Bio has won the Innovation Award at the UK’s largest laboratory event, held at the NEC Birmingham in November. PhysioMimix™ allows researchers to set up assays and generate results quickly. Scientists and...
CN Bio Innovations’ Board names David Hughes as next Chief Executive Officer
London, UK, 19 July 2018: CN Bio Innovations Limited today announced that its Board of Directors has accepted the resignation of Dr Emma Sceats as CEO and Director of CN Bio and appointed Dr David Hughes as Chief Executive Officer effective immediately. Dr Hughes has...
Organ-on-Chip Webinar: Improving Preclinical Studies for Faster Drug Development
View this webinar by industry specialists Xtalks to discover how to run Organ-on-a-Chip studies in your own lab to enhance research. The webinar covers: Walkthrough of an Organ-on-Chip workflow: lab set-up, seeding and culturing cells, dosing, sampling and analysis...
CN Bio launches PhysioMimix benchtop Human-Body-on-a-Chip device
London, UK, 23 May 2018: CN Bio Innovations Limited today launched PhysioMimix, a printer-sized device which allows scientist to conduct organ-on-chip studies in their own labs, testing new drugs and chemicals on living human organ models. Dr Emma Sceats, CEO of CN...